Physician profile
Tamara Moss
NPI 1134143282
$7,509.21
in general payments reported to CMS, 2019-2025
39 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $830 · 2021: $1,194 · 2022: $1,225 · 2023: $1,533 · 2024: $1,248 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,838.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.61 | 2020-2025 | |
| Amgen INC. | $612.41 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $556.64 | 2021-2025 | |
| Genzyme Corporation | $489.10 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $483.49 | 2019-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $436.16 | 2023-2025 | Sotyktu |
| Incyte Corporation | $389.08 | 2021-2025 | Opzelura |
| Merz North America, INC. | $382.52 | 2020-2023 | Xeomin |
| Leo Pharma INC. | $345.28 | 2019-2025 | Adbry |
| Vyne Pharmaceuticals INC. | $285.13 | 2020-2021 | |
| Galderma Laboratories, L.P. | $270.79 | 2019-2025 | |
| Janssen Biotech, INC. | $240.44 | 2022-2025 | Tremfya, Remicade, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.64 | 2019-2023 | Xifaxan |
| Pfizer INC. | $214.82 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $189.80 | 2023-2025 | Zoryve |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.